EANS-Voting Rights: Epigenomics AG / Release according to article 26, section 1 WpHG (Securities Trading Act) with the aim of Europe-wide distribution

--------------------------------------------------------------------------------
Notification of voting rights transmitted by euro adhoc. The issuer is
responsible for the content of this announcement.
--------------------------------------------------------------------------------

Announcement according to Article 21, Section 1 of the WpHG (share)

Voting Rights: Release of a Voting Rights Notification Pursuant to Sec. 26 para.
1 WpHG (German Securities Trading Act) with the Aim of a Europe-wide
Distribution

Issuer:

Epigenomics AG
Kleine Präsidentenstr. 1
10178 Berlin
Germany

Voting Rights Notification:

On 18 October 2012, Baker Bros. Advisors, LLC, New York, NY, USA notified
Epigenomics AG of voting rights in Epigenomics AG pursuant to sec. 21 para. 1
WpHG in connection with sec. 22 para. 1 sent. 1 no. 6 WpHG as follows:

On 12 October 2012, the share of Baker Bros. Advisors, LLC in the voting rights
of Epigenomics AG fell below the 3 per cent threshold of sec. 21 para. 1 WpHG
and amounted, as at this date, to 2.76 per cent of the voting rights (243,264
voting rights) in Epigenomics AG.

2.76 per cent of the voting rights (243,264 voting rights) are attributed to
Baker Bros. Advisors, LLC, pursuant to sec. 22 para. 1 no. 6 WpHG.

Furthermore, on 18 October 2012, Julian C. Baker, USA, notified Epigenomics AG
of voting rights in Epigenomics AG pursuant to sec. 21 para. 1 WpHG in
connection with sec. 22 para. 1 sent. 1 no. 1 and no. 6, sent.2 WpHG and sec. 22
para. 2 WpHG as follows:

On 12 October 2012, the share of Julian C. Baker in the voting rights of
Epigenomics AG fell below the 3 per cent threshold of sec. 21 para. 1 WpHG and
amounted, as at this date, to 2.76 per cent of the voting rights (243,264 voting
rights) in Epigenomics AG.

All 2.76 per cent of the voting rights (243,264 voting rights) are attributed to
Julian C. Baker pursuant to sec. 22 para. 1 sent. 1 no. 1 WpHG.

The 2.76 per cent of the voting rights (243,264 voting rights) are also
attributed to Julian C. Baker pursuant to sec. 22 para. 1 sent. 1 no. 6, sent. 2
WpHG. In addition, all 2.76 per cent of the voting rights are attributed to
Julian C. Baker pursuant to sec.22 para.2 WpHG.

Furthermore, on 18 October 2012, Felix J. Baker, USA, notified Epigenomics AG of
voting rights in Epigenomics AG pursuant to sec. 21 para. 1 WpHG in connection
with sec. 22 para. 1 sent. 1 no.1 and no. 6, sent. 2 WpHG and sec. 22 para. 2
WpHG as follows:

On 12 October 2012, the share of Felix J. Baker in the voting rights of
Epigenomics AG fell below the 3 per cent threshold of sec. 21 para. 1 WpHG and
amounted, as at this date, to 2.76 per cent of the voting rights (243,264 voting
rights) in Epigenomics AG.

All 2.76 per cent of the voting rights (243,264 voting rights) are attributed to
Felix J. Baker pursuant to sec. 22 para. 1 sent. 1 no.1 WpHG.

The 2.76 per cent of the voting rights (243,264 voting rights) are also
attributed to Felix J. Baker pursuant to sec. 22 para. 1 sent. 1 no. 6, sent. 2
WpHG. In addition, all 2.76 per cent of the voting rights are attributed to
Felix J. Baker pursuant to sec. 22 para.2 WpHG.

Furthermore, on 18 October 2012, Baker Brothers Life Sciences Capital (GP), LLC,
New York, NY, USA notified Epigenomics AG of voting rights in Epigenomics AG
pursuant to sec. 21 para. 1 WpHG in connection with sec. 22 para. 1 sent. 1 no.
1 WpHG and sec. 22 para. 2 WpHG as follows:

On 12 October 2012, the share of Baker Brothers Life Sciences Capital (GP), LLC
in the voting rights of Epigenomics AG fell below the 3 per cent threshold of
sec. 21 para. 1 WpHG and amounted, as at this date, to 2.76 per cent of the
voting rights (243,264) in Epigenomics AG.

2.69 per cent of the voting rights (237,282 voting rights) are attributed to
Baker Brothers Life Sciences Capital (GP), LLC pursuant to sec. 22 para. 1 sent.
1 no. 1 WpHG.

0.07 per cent of the voting rights (5,982 voting rights) are attributed to Baker
Brothers Life Sciences Capital (GP), LLC pursuant to sec. 22 para. 2 WpHG.

Furthermore, on 18 October 2012, Baker Brothers Life Sciences Capital, L.P., New
York, NY, USA notified Epigenomics AG of voting rights in Epigenomics AG
pursuant to sec. 21 para. 1 WpHG in connection with sec. 22 para. 1 sent. 1 no.
1 WpHG and sec. 22 para. 2 WpHG as follows:

On 12 October 2012, the share of Baker Brothers Life Sciences Capital, L.P. in
the voting rights of Epigenomics AG fell below the 3 per cent threshold of sec.
21 para. 1 WpHG and amounted, as at this date, to 2.76 per cent of the voting
rights (243,264) in Epigenomics AG.

2.69 per cent of the voting rights (237.282 voting rights) are attributed to
Baker Brothers Life Sciences Capital, L.P. pursuant to sec. 22 para. 1 sent. 1
no. 1 WpHG.

0.07 per cent of the voting rights (5,982 voting rights) are attributed to Baker
Brothers Life Sciences Capital, L.P. pursuant to sec. 22 para. 2 WpHG.

Furthermore, on 18 October 2012, Baker Brothers Life Sciences, L.P., New York,
NY, USA notified Epigenomics AG of voting rights in Epigenomics AG pursuant to
sec. 21 para. 1 WpHG in connection with sec. 22 para. 2 WpHG as follows:

On 12 October 2012, the share of Baker Brothers Life Sciences, L.P. in the
voting rights of Epigenomics AG fell below the 3 per cent threshold of sec. 21
para. 1 WpHG and amounted, as at this date, to 2.76 per cent of the voting
rights (243,264 voting rights) in Epigenomics AG.

0.07 per cent of the voting rights (5,982 voting rights) are attributed to Baker
Brothers Life Sciences, L.P. pursuant to sec. 22 para. 2 WpHG.

Furthermore, on 18 October 2012, 14159 Capital (GP), LLC, New York, NY, USA
notified Epigenomics AG of voting rights in Epigenomics AG pursuant to sec. 21
para. 1 WpHG in connection with sec. 22 para. 1 sent. 1 no. 1 WpHG and sec. 22
para.2 WpHG as follows:

On 12 October 2012, the share of 14159 Capital (GP), LLC in the voting rights of
Epigenomics AG fell below the 3 per cent threshold of sec. 21 para. 1 WpHG and
amounted, as at this date, to 2.76 per cent of the voting rights (243,264 voting
rights) in Epigenomics AG.

0.07 per cent of the voting rights (5,982 voting rights) are attributed to 14159
Capital (GP), LLC pursuant to sec. 22 para. 1 sent. 1 no. 1 WpHG.

2.69 per cent of the voting rights (237,282 voting rights) are attributed to
14159 Capital (GP), LLC pursuant to sec. 22 para. 2 WpHG.

Furthermore, on 18 October 2012, 14159 Capital, L.P., New York, NY, USA notified
Epigenomics AG of voting rights held in Epigenomics AG pursuant to sec. 21 para.
1 WpHG in connection with sec. 22 para. 1 sent. 1 no. 1 WpHG and sec. 22 para.2
WpHG as follows:

On 12 October 2012, the share of 14159 Capital, L.P. in the voting rights of
Epigenomics AG fell below the 3 per cent threshold of sec. 21 para. 1 WpHG and
amounted, as at this date, to 2.76 per cent of the voting rights (243,264 voting
rights) in Epigenomics AG.

0.07 per cent of the voting rights (5,982 voting rights) are attributed to 14159
Capital, L.P. pursuant to sec. 22 para. 1 sent. 1 no. 1 WpHG.

2.69 per cent of the voting rights (237,282 voting rights) are attributed to
14159 Capital, L.P. pursuant to sec. 22 para. 2 WpHG.

Furthermore, on 18 October 2012, 14159, L.P., New York, NY, USA, notified
Epigenomics AG of voting rights in Epigenomics AG pursuant to sec. 21 para. 1
WpHG in connection with sec. 22 para.2 WpHG as follows:

On 12 October 2012, the share of 14159, L.P. in the voting rights of Epigenomics
AG fell below the 3 per cent threshold of sec. 21 para. 1 WpHG and amounted, as
at this date, to 2.76 per cent of the voting rights (243,264 voting rights) in
Epigenomics AG.

2.69 per cent of the voting rights (237,282 voting rights) are attributed to
14159, L.P. pursuant to sec.22 para. 2 WpHG.

Date of release: 19 October 2012

Epigenomics AG
The Executive Board

Further inquiry note:
Antje Zeise | CIRO
Manager IR/PR
Epigenomics AG
Tel: +49 30 24345 386
antje.zeise@epigenomics.com

end of announcement euro adhoc
--------------------------------------------------------------------------------

issuer: Epigenomics AG
Kleine Präsidentenstraße 1
D-10178 Berlin
phone: +49 30 24345-0
FAX: +49 30 24345-555
mail: ir@epigenomics.com
WWW: http://www.epigenomics.com
sector: Biotechnology
ISIN: DE000A1K0516
indexes: Prime All Share, Technology All Share
stockmarkets: free trade: Berlin, München, Hamburg, Düsseldorf, Stuttgart,
regulated dealing/prime standard: Frankfurt
language: English